Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Venetoclax for #CLL After BTK Inhibitors: What Patients Should Know | EHA 2026
HealthTreeDescription
Dr. Thomas Chatzikonstantinou from Greece presents research on CLL patients who switched from BTK inhibitors to venetoclax-based treatment.
THE STUDY:
International research looking at CLL patients who:
1. First received BTK inhibitors (a common first-line treatment)
2. Stopped that treatment due to disease progression or side effects
3. Then switched to venetoclax-based therapy
KEY FINDINGS:
Venetoclax is a very effective CLL treatment. However, patients who switched to it AFTER their disease progressed on BTK inhibitors had poorer outcomes compared to patients getting venetoclax in other situations.
WHY THIS MATTERS:
This research shows that the order and timing of treatments matters. When CLL develops resistance to one drug, starting a new drug becomes harder. Understanding this helps doctors plan treatment sequences better, know which patients might need different strategies, and design better clinical trials to improve outcomes.
THE TAKEAWAY:
If you're a CLL patient, this research highlights the importance of catching disease progression early and working with your doctor on the best treatment plan for your situation.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction
0:10 About BTK Inhibitors in CLL
0:25 Why Patients Switch Treatments
0:43 The Research Question
0:57 Why We Need This Study
1:19 How Effective is Venetoclax?
1:28 The Challenge: Switching After Progression
1:45 How This Study Was Done
1:53 What This Means for Future Trials
2:09 Key Finding & Next Steps
#CLL #VenetoclaxTherapy #BTKInhibitors #Research